Skip to main content
Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.2060
-0.0140 (-6.36%)
At close: Mar 28, 2025, 4:00 PM
0.2002
-0.0058 (-2.82%)
After-hours: Mar 28, 2025, 4:36 PM EDT

Adaptimmune Therapeutics Revenue

In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth. Adaptimmune Therapeutics had revenue of $3.22M in the quarter ending December 31, 2024, with 1,294.81% growth.

Revenue (ttm)
$178.03M
Revenue Growth
+195.34%
P/S Ratio
0.31
Revenue / Employee
$351,842
Employees
506
Market Cap
52.99M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024178.03M117.75M195.34%
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

ADAP News

More News